Treatment of metastatic castration-resistant prostate cancer (mCRPC) remains clinically challenging due to tumor heterogeneity and drug resistance. Microtubule-targeting agents are a mainstay of mCRPC therapy, but limitations persist regarding progression-free survival. Pterocarpans have emerged as ...
ORGANISM(S): Homo sapiens (Human)